ONO-7475 + ONO-7475 + ONO-4538

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced or Metastatic Solid Tumors

Conditions

Advanced or Metastatic Solid Tumors

Trial Timeline

Oct 17, 2018 → Nov 22, 2022

About ONO-7475 + ONO-7475 + ONO-4538

ONO-7475 + ONO-7475 + ONO-4538 is a phase 1 stage product being developed by Ono Pharmaceutical for Advanced or Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03730337. Target conditions include Advanced or Metastatic Solid Tumors.

What happened to similar drugs?

16 of 20 similar drugs in Advanced or Metastatic Solid Tumors were approved

Approved (16) Terminated (1) Active (4)
ApatinibTabletsJiangsu Hengrui MedicineApproved
letrozoleJiangsu Hengrui MedicineApproved
FulvestrantAstraZenecaApproved
Zoladex and CasodexAstraZenecaApproved
GefitinibAstraZenecaApproved
Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03730337Phase 1Completed

Competing Products

20 competing products in Advanced or Metastatic Solid Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21